- Home
- LYFT vs IOVA Comparison
LYFT vs IOVA Comparison
Compare LYFT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | IOVA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 968.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYFT | IOVA |
|---|---|---|
| Price | $19.36 | $2.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 12 |
| Target Price | ★ $22.55 | $10.45 |
| AVG Volume (30 Days) | 11.4M | ★ 11.5M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $6,273,827,000.00 | $250,425,000.00 |
| Revenue This Year | $14.34 | $60.71 |
| Revenue Next Year | $14.00 | $59.52 |
| P/E Ratio | $53.22 | ★ N/A |
| Revenue Growth | 14.90 | ★ 175.62 |
| 52 Week Low | $9.66 | $1.64 |
| 52 Week High | $25.54 | $8.15 |
Technical Indicators
Market Signals| Indicator | LYFT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 60.78 |
| Support Level | $19.08 | $2.69 |
| Resistance Level | $19.78 | $2.89 |
| Average True Range (ATR) | 0.62 | 0.17 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 34.58 | 70.88 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.